Alterity Therapeutics Warrant ATHDB Shows No Trading Activity
The ATHDB warrant on Australia's ASX has recorded zero trades, signaling extremely thin liquidity for this instrument.
Alterity Therapeutics Ltd's warrant, designated ATHDB and listed on the Australian Securities Exchange, has recorded no trading activity, according to financial data tracked by TradingView. The warrant, formally titled Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery, carries a stated expiration date of August 31, 2026.
The absence of any completed trades is a notable marker of illiquidity, a condition that can expose investors to wide bid-ask spreads and difficulty entering or exiting positions at favorable prices. Warrants with deferred delivery structures are already considered more complex instruments, and a lack of market participation compounds that complexity.
Read more VeriSign Financials: Revenue, Margins, and Peer Comparison →
For retail investors monitoring small-cap biotech warrants, the ATHDB data serves as a practical reminder that not all exchange-listed instruments maintain active secondary markets. Thin or nonexistent volume can make published price data unreliable as a guide to fair value, since no arm's-length transactions have established a clearing price.
Alterity Therapeutics is an Australian biopharmaceutical company, and its associated warrant instruments trade separately from its ordinary shares. Investors considering any position in ATHDB should weigh the liquidity risk carefully alongside any underlying thesis on the company's drug development pipeline before committing capital.
Continue reading at TradingView.
